Alle afleveringen
364 afleveringen, van nieuw naar oud
-
AI, start-ups, and the future of human health: AION Labs’ Mati Gill
27 oktober 2026 · 20 min
In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest. Lees meer
AION Labs is a venture studio built by a coalition of pharma heavyweights, tech giants, and leading investors to develop and integrate AI technologies to redefine drug discovery and development through the creation of new start-ups.
Gill discusses some great start-ups coming out of the AION Labs co-development model, what investors now expect of AI biotech companies, and the potential of AI in drug discovery and development for the good of human health.
You can listen to episode 284 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
ESMO26: Taiho Oncology on improving the lives of patients with cancer, their families, and their caregivers
26 oktober 2026 · 17 min
At ESMO 2026, Taiho Oncology presented data from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (or NSCLC) harbouring epidermal growth factor receptor (or EGFR) exon 20 insertion mutations or other uncommon EGFR mutations and active central nervous system (or CNS) metastases. Lees meer
During the Congress, pharmaphorum’s Nicole Raleigh invited Dr Harold Keer, chief medical officer at Taiho Oncology, as a guest on the podcast while he was on the ground in Madrid, Spain.
Dr Keer discusses the non-small cell lung cancer patient and treatment setting, as well as improving the lives of patients with cancer, their families, and their caregivers. He also goes into detail on Taiho’s orally administered anti-cancer agents for various tumour types and an expanding pipeline of antibody-drug conjugate (or ADC) therapies.
Listen to the conversation and explore our updates from ESMO 2026 here.
-
ESMO26: Lowering toxicity, extending lives, with Syncromune
23 oktober 2026 · 11 min
As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast for a conversation on the updated long-term overall survival data from its Phase 1 trial of SYNC-T Therapy SV-102 in patients with metastatic prostate cancer. Lees meer
Dr Link discusses SYNC-T, their investigational in situ personalised immunotherapy, as well as metastatic castration-resistant (or mCRPC) and metastatic hormone-sensitive (or mHSPC) disease, and the possible outcomes for patients going forward.
Listen to the conversation and keep up on ESMO26 updates here.
-
Menopause is an urgent global health issue: Bayer’s Cecilia Caetano
20 oktober 2026 · 31 min
*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* Lees meer
By 2030, 1.2 billion women worldwide will be menopausal or post-menopausal - many at the peak of their working lives. Yet, menopause remains largely absent from health system planning, despite growing evidence linking unmanaged symptoms to reduced productivity, absenteeism, and women leaving the workforce altogether.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Cecilia Caetano, vice president, global medical affairs and evidence generation lead in women’s health at Bayer, for a conversation on this overlooked, but increasingly urgent global health issue.
Caetano discusses the lack of innovation in women’s health and, critically, the lack of understanding of menopausal needs. She also explores the European landscape for menopause in comparison to the UK, as well as describing what ‘health system readiness’ looks like.
You can listen to episode 281 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*
-
AI governance & cybersecurity: Torridon Cyber’s Robbie Tyrie
13 oktober 2026 · 23 min
Even the most promising innovation still depends on strong governance, resilient operations, and confidence in sensitive data. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Robbie Tyrie, founder and managing director of Torridon Cyber, for a conversation on cybersecurity when it comes to pharma companies and health systems more widely.
Tyrie shares his insights and explains how to ensure cybersecurity acts as a business enabler, as opposed to a barrier to growth.
You can listen to episode 280 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
AI and pharma launch - Within3's Jason Smith
6 oktober 2026 · 16 min
Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments. Lees meer
In a new pharmaphorum podcast, host Nicole Raleigh speaks with Jason Smith, CTO of AI and analytics at Within3, for a conversation on data-fuelled agile launches and smarter decision-making.
Smith discusses alignment of cross-functional teams and fostering real collaboration and efficiency, how pharma teams can use real-time data to shape more precise and effective launch strategies, and the importance in all this of maintaining a deep focus on patient needs and healthcare provider challenges.
You can listen to episode 279 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Bioconvergence & future human health, with Shai Melcer
1 oktober 2026 · 30 min
Bioconvergence is a multidisciplinary research and development approach that merges technologies from biology, engineering, and computation, providing solutions in medicine, food, agriculture, manufacturing, climate, and more. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Shai Melcer, head of the national bioconvergence programme at Israel Innovation Authority, for a conversation exploring bioconvergence broadly.
Melcer discusses the foundations, goes into detail about companies currently working in the bioconvergence space, and what it could – all together – mean for the future of human health.
You can listen to episode 278 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
AI-enabled pharmacovigilance, with Updesh Dosanjh
24 september 2026 · 31 min
Artificial intelligence is dramatically transforming the landscape for every part of pharma. One area where AI is both essential to implement and important to get right is pharmacovigilance, the group concerned with monitoring and maintaining patient safety. Lees meer
In today's pharmaphorum podcast, sponsored by IQVIA Safety Solutions, host Jonah Comstock speaks with Updesh Dosanjh, IQVIA commercialisation lead for safety technology, about how and why the role of AI in pharmacovigilance is changing, as well as tips for implementing these new tools safely and reliably.
Dosanjh discusses why AI in pharmacovigilance is moving beyond document extraction and case processing, how regulatory expectations are shifting from basic compliance to meaningful patient outcomes, and why governance and monitoring matter more than technology alone.
Then, in the second half of the conversation, he covers how organisations can build trust and adoption across their teams, what patient-level safety monitoring could look like in the era of personalised medicine, and, finally, why starting with a meaningful, high-value use case is critical to AI success.
Check out the full podcast below, and then download the White Paper to learn even more.
-
Getting predictive technologies to patients, with Concr
22 september 2026 · 19 min
Earlier this year, the FDA released draft guidance endorsing Bayesian methods and simulation-based evidence in clinical trials in a significant shift in how regulators think about predictive medicine. Lees meer
In a new pharmaphorum podcast, Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static, one-test-one-answer diagnostics, as well as the potential of digital twins, and how, if regulators keep approving AI medical tools the way they approve blood tests, the most promising predictive technologies will never reach patients.
You can listen to episode 276 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Europe for life sciences and for patients, with BeOne Medicines
15 september 2026 · 18 min
*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* Lees meer
Europe continues to offer major life sciences advantages: deep scientific talent, strong clinical expertise, mature research infrastructure, and significant manufacturing capability. Indeed, biotech companies continue to invest in Europe as a long-term hub for scientific innovation, clinical research, and economic growth.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Giancarlo Benelli, SVP & Head of Europe at BeOne Medicines, for a conversation on what Europe must do, however, in order to remain globally competitive.
Benelli discusses EFPIA’s latest reports on Europe’s competitiveness as a location for the life sciences industry, as well as exploring why it is at the same time losing ground to the US and to China. Additionally, Benelli comments on the importance of regulatory stability looking forward.
You can listen to episode 275 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*
-
Ethical AI & trust-driven innovation: UCB’s Erik Janssen
8 september 2026 · 16 min
*This episode of the pharmaphorum podcast is brought to you in association with Klick Health* Lees meer
When it comes to digital innovation and AI, consideration of using and implementing such responsibly and ethically ever more becomes forefront. But how can pharma lead the way in ethical AI and trust-driven innovation?
In a new pharmaphorum podcast, Erik Janssen, head of digital care transformation at UCB, joins web editor Nicole Raleigh for a conversation on responsible digital innovation and ethical AI.
Janssen discusses how pharma can lead in responsible experimentation by focusing digital innovation on enhancing (not replacing) human care. He also speaks about co‑creating solutions with clinicians and patients, as well as the role of evidence‑based technology across the innovation framework.
You can listen to episode 274 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*
-
Delivering prevention at scale, PA Consulting’s James Davis
25 augustus 2026 · 16 min
Public demand for prevention is surging, with 33.6 million people now using the NHS App, yet, NHS leaders say the digital infrastructure required to deliver prevention at scale isn’t in place. Lees meer
In a new episode of the podcast, pharmaphorum spoke with James Davis, a healthcare expert at PA Consulting, for a conversation on the digital foundations needed to unlock a prevention first NHS.
Davis also discusses the initiatives with the biggest near term impact, what NHS leaders are worried about, and issues of trust and inequality.
You can listen to episode 273 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Understanding Operation Trialblazer, with Dr Harpreet Singh
19 augustus 2026 · 36 min
For a variety of reasons, early stage clinical trials have been moving out of the United States more and more over the past few years, as companies pursue savings and lighter regulatory burden in places like China and Australia. The industry has long urged the US government to take some action to make it more attractive to bring these trials back to the States. That's the broad idea behind Operation TRIALBLAZER, a campaign launched this summer by HHS and the FDA. Lees meer
On today's podcast, host Jonah Comstock is joined by Dr Harpreet Singh, currently chief medical officer at Precision for Medicine. That's her first private sector job after nearly nine years at the FDA, so she's able to bring both an insider and outsider perspective in discussing this initiative.
In addition to sharing some details about her time at the FDA and how the organisation has changed, Dr Singh discusses the situation in clinical research that's led to the US' leadership in clinical trials slipping away, what's in the Trialblazer plans, and whether she thinks it will be enough to turn the tide.
They also talk a little bit about radiotherapeutics regulation and discuss why having clinical trials in the United States is important not just for the economy, but also for patients who are missing out on opportunities for cutting-edge care.
Tune in for a fascinating primer on a major new US government clinical trials initiative.
-
Prevent-Stop-Cure: Diagnostics & chronic liver disease, with Roche
4 augustus 2026 · 15 min
Chronic liver disease affects around 1.5 billion people globally. As understanding of liver disease improves, outcomes are increasingly determined by how early patients are identified, not just what therapies are available. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lee Lehman Becker, Roche’s global head of healthcare insights at Roche Information Solutions (RIS), for a discussion of the liver disease epidemic that is being diagnosed too late and driving a growing health system crisis globally.
The conversation also explores scalable diagnostic innovation and the role of this in addressing health system burden – metabolic liver disease projected to affect some 1.8 billion people by 2050, with global costs expected to exceed $2.3 trillion.
You can listen to episode 271 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran
30 juli 2026 · 30 min
The drug price negotiation provisions in the Inflation Reduction Act were designed to continue evolving with each passing year. As CMS prepares for 2028 and 2029, the agency has put out new draft guidance codifying and, in some cases, modifying the fine print of the controversial law. They’ve also recently issued additional draft guidance on how they’ll handle the imminent introduction of Part B drugs into the programme. Lees meer
Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum editor-in-chief Jonah Comstock to elucidate some of the finer points of this latest communication from CMS – and to urge the industry to take advantage of the public comment periods associated with it.
Curran and Comstock discuss small, but impactful, changes in CMS’s policies around deemed biologics, vaccines, and the special provisions that protect small biotechs. And Curran gives a rundown of what’s in – as well as what’s not in – the new MFP effectuation guidance, laying out how the differences in how Part D and Part B drugs are paid for leave some big question marks hanging over the programme.
Tune in for an easy-to-understand deep dive into some complicated subject matter, and for a more comprehensive rundown don’t forget to check out Hogan Lovells’ policy briefs on the new draft rules and the MFP effectuation guidance.
-
CAMP4 on a new class of ASO in gene under expression
21 juli 2026 · 17 min
SYNGAP1-related disorder negatively impacts synaptic signalling during critical periods of brain development, leading to a range of cognitive, epileptic, behavioural, and motor symptoms. Lees meer
In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Kelly Gold, CFO of CAMP4 Therapeutics, about antisense oligonucleotides (or ASOs) - medicines designed to selectively restore natural protein production in diseases caused by gene under expression.
Gold discusses the space and CAMP4’s CMP-002 study, targeting the regRNA associated SYNGAP1 gene. You can listen to episode 269 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
BonelliErede on M&A in Europe: Andrea Carta Mantiglia
14 juli 2026 · 20 min
The M&A market has been rebounding in the US, driven by factors like patent cliffs and improved balance sheets – but the question is whether this will play out in Europe and how the wave could differ. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, about whether the current US biotech M&A surge will indeed extend into Europe.
The conversation touches upon the appetite for cross-border dealmaking, the growing role of private equity in European pharma and medtech, generational exits among family-owned pharma groups in Italy, and the role of digitalisation in all this.
You can listen to episode 268 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Purespring on nephrology & gene therapy in kidney disease
7 juli 2026 · 15 min
Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Haseeb Ahmad, CEO of Purespring, who discusses transforming the treatment of kidney disease, an area of enormous unmet need, with more than 840 million people worldwide living with chronic kidney disease.
Indeed, Purespring’s lead programme is the podocyte-targeted gene therapy PS-002, which is for IgA nephropathy (or IgAN). The conversation also touches upon the evolution of the gene therapy landscape more generally, and where next with this type of innovation in the nephrology space.
You can listen to episode 267 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Parexel: Flawless execution, policy shifts & patient-centric design
30 juni 2026 · 15 min
Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh caught up with Paul Bridges, president, consulting, at Parexel, and Charlotte Moser, Parexel’s chief medical officer, following BIO-Europe Spring in Lisbon, Portugal.
The conversation touches upon regulatory strategy and evolving policy shifts, trial design and execution – and the importance of patient centricity – as well as AI in drug development and medical leadership in drug development today.
You can listen to episode 266 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Citius’ Leonard Mazur talks targeted immune therapy for CTCL
23 juni 2026 · 13 min
Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune system. And Citius Oncology is focused on developing and commercialising a targeted immune therapy for the initial indication of the treatment of persistent or recurrent CTCL. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals about the launch of its first FDA-approved drug, Lymphir, for CTCL.
Mazur discusses the landscape of unmet need in this space, as well as Citius’ advancement of clinical trials in other areas without approved treatments and the future horizon for such oncological innovations.
You can listen to episode 265 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey
17 juni 2026 · 15 min
The radiopharmaceutical sector is in the midst of a transformative year in 2026, with significant developments and challenges, including policy and reimbursement, increasing demand and growth within precision oncology and molecular imaging, and the need for specialised CDMOs when it comes to the intricate nature of radiopharmaceutical manufacturing. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Andrew Cavey, CEO of ITM, about current and future radiopharmaceutical trends.
Dr Cavey discusses the evolution of radiopharma, beyond the original “two pillars” of GEP-NETs and PSMA, including the move towards a multi-isotope model, as well as ITM’s pipeline and the potential growth of the broader radiopharma ecosystem going forward.
You can listen to episode 263 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Biosimilars & patient access independent of geographies or socioeconomics, with Rebecca Guntern
10 juni 2026 · 13 min
2026 is the year of a major wave of pharmaceutical patent expirations, with numerous blockbuster drugs – spanning diabetes, immunology, cardiovascular, oncology, and other therapeutic areas – on the verge of losing market exclusivity. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Rebecca Guntern, chief commercial officer at Sandoz, for a conversation on the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.
Guntern discusses why the current wave of blockbuster biologics losing exclusivity is so significant for patient access and healthcare budgets, and the conversation also touches upon policy and regulatory changes still needed in order to unlock the full potential of biosimilars, as well as what should be expected from the next generation of biosimilars.
You can listen to episode 263 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Towards a healthier world: Momentum in UK health system transformation, with Lee-Ann Farrell
2 juni 2026 · 24 min
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson, about what delivery will look like in practice when it comes to the National Cancer Plan, the 10-Year Health Plan, and the Life Sciences Sector Plan. Lees meer
The conversation ranges what comes next following the clear policy direction of the Plans, including how the system can move from ambition to implementation, particularly in ensuring innovation is adopted consistently and at pace across cancer care.
Farrell discusses the role of innovative medicines within evolving care pathways – as ambitions grow around earlier diagnosis, improved outcomes, and care closer to home – as well the dual role of innovative medicines, both as drivers of better patient outcomes and as contributors to economic growth and system sustainability.
You can listen to episode 262 to go here of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Trustworthy and novel AI in clinical trial planning, with Kris Kaneta
26 mei 2026 · 18 min
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Kris Kaneta, chief product officer at Norstella, which is helping life sciences companies speed up development with instant strategy recommendations. Lees meer
Kaneta discusses AI in drug trials and commercialisation and just what’s possible when clinical AI has access to a data set robust enough to allow it to make real strategic recommendations.
Kaneta also touches upon why patient-level data is pharma's most important asset in the AI race and the roadblocks that stand in the way of further expanding the efficacy of AI for clinical trials.
You can listen to episode 261 to go here of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
The cardio-renal-metabolic space and obesity as a chronic disease, with Ramy Younes
19 mei 2026 · 16 min
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Ramy Younes, Corporate Vice President, Global Head of Clinical Development, CardioRenalMetabolism, at Boehringer Ingelheim. Lees meer
The conversation explores the crisis beyond obesity that many clinicians and health systems are now grappling with: that obesity can’t be treated as a short-term, weight-loss lifestyle issue. Rather, it needs to be managed as a complex, chronic, multi-organ disease.
Younes discusses how liver disease is often missed in cardiometabolic risk and is referred to as the ‘liver blind spot’, as well as what integrated pathways can do to improve outcomes and ease system pressure.
-
On the power of T-cells, with Cedrik Britten
12 mei 2026 · 18 min
In a new pharmaphorum podcast, web editor Nicole Raleigh sat down with Dr Cedrik Britten, chief medical officer at Immatics, to discuss novel PRAME-directed T-cell immunotherapies. Lees meer
Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need. And to do so safely and effectively requires deep expertise in immunology, drug development, and beyond.
Britten explains how finding the right cancer target is only half the equation – the other half is creating the key that fits the lock to that cancer. So it is that, in addition to discovery of tumour-specific targets like PRAME, Immatics designs either engineered T-cell receptors (or TCRs) or bispecific molecules that recognise and bind to those targets.
Britten also shares his dreams for the future of the field; his hopes far into the distant horizon.
You can listen to episode 259 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Why everyone should care about longevity, with Boyang Wang
5 mei 2026 · 27 min
Longevity and healthspan have emerged rapidly as an increasingly serious category of healthcare study and investment. But there are a lot of ideas inside the industry and out about exactly what the goal is. Is it about extending lifespans as much as possible? Are we trying to live forever? Or do we just want to experience less physical and cognitive decline as we age? Lees meer
In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Boyang Wang, the founder of Immortal Dragons, a $40 million Singapore-based fund focusing exclusively on moonshot longevity innovations.
In a broad-ranging conversation, they talk about popular misconceptions about the longevity space and why it’s something that everyone should care about. They talk a bit about specific areas of investment for Immortal Dragons like organ synthesis and gene therapy. And they try to look ahead into the future of a space which is all about getting us to that future alive and well.
-
A philosophical look at market turn in the Age of AI, with John Holodnak
28 april 2026 · 21 min
Today, the life sciences sector is prioritising recruitment of leaders who can scale efficiently in capital-constrained environments, as well as focusing on hybrid operator-strategists who can integrate AI into R&D, clinical, and commercial workflows. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with John Holodnak, co-founder of Occam, about how AI is beginning to reshape career paths across life sciences.
Holodnak discusses AI’s transformation of functional roles in life sciences, such as regulatory, market access, and business development, and explores the breakdown of linear career paths and way ahead for biotech and pharma professionals tomorrow.
You can listen to episode 257 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Providing patient access to new therapies, with Dean Erhardt
22 april 2026 · 18 min
Pharma and tech companies are working more closely together than ever. As proven by the news of Merck and NVidia’s new partnership, for example. But while the idea of using AI for drug discovery has been around for a while now, patient access has an awfully long way to catch up to the promise of these new therapies. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dean Erhardt, founder of D2 Solutions, an end-to-end strategic partner delivering industry-leading consulting and purpose-built technologies to pharma manufacturers, hospitals, pharmacies, payers & PBMs.
The conversation focuses on the disconnect between distributions, reimbursements, and patient services, particularly when it comes to speciality medicines, as well as patient access today versus the state of patient access tomorrow, and the benefit or otherwise of price protection guarantees with PBMs, when it comes to new therapies.
You can listen to episode 256 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Pushing through barriers to commercial launch success, with Amanjeet Singh Saluja
16 april 2026 · 19 min
Despite billions spent on new technology and improving data analytics, companies continue to struggle with commercial launch success, with around 35% of launches missing expectations since 2012. Lees meer
Why is launch underperformance such a big problem, and why isn’t technology alone offering a sufficient solution? In a special episode of the pharmaphorum podcast, sponsored by Axtria, we spoke with Amanjeet Singh Saluja, a Principal at Axtria, about the current state of affairs in launch success.
In our conversation, Singh Saluja digs into the strategic and institutional causes of failed launches and what strategies can help redeem them. He also discusses some of the external forces that have reshaped the pharma commercialisation industry, and how to keep pace with those trends and changes.
Finally, of course, we talk about agentic AI. Even though it may not be a silver bullet, when used correctly, in the right strategic context, it can make a big difference.
Meet Singh Saluja and other senior life sciences commercialisation leaders at Axtria Ignite 2026, an invitation-only event where the industry works through these challenges and more. June 10-11th in Princeton, NJ. Register here.
About the Interviewee
Amanjeet Singh Saluja is a seasoned leader in AI, analytics, and cloud software. He currently heads a Strategic Business Unit at Axtria Inc., a leading global provider of AI and cloud solutions to the life sciences industry. Singh Saluja has built, scaled, and exited three successful ventures, and is the original inventor of a US patent for collection cycle optimisation through advanced analytics. He brings 26 years of experience advising Fortune 500 clients in financial services, life sciences, and MedTech on risk management, commercial strategies, and artificial intelligence. He has been recognised in Marquis Who’s Who in 2025.
Singh Saluja is particularly skilled at driving growth, improving sales efficiency, optimising costs, cultivating high-performing teams, …
-
Every drug is a story, with Thomas Goetz
14 april 2026 · 32 min
Here at pharmaphorum we tend to focus on the latest developments in the pharmaceutical space. And to be fair, that’s quite a lot to keep us busy. But the history of pharma is full of incredible stories that might just be new to a lot of people, even those inside the industry. Lees meer
On today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Thomas Goetz, former executive editor of Wired; co-founder of Iodine, a drug data company that was acquired by GoodRx; and, most recently, creator and host of the Drug Story podcast.
Each episode of Drug Story dives into the story behind a particular drug and the condition that it treats, unlocking fascinating morsels of history and, indeed, current controversies along the way.
Goetz discusses the inspiration for the show and what he hopes listeners will take away from it. He also talks about how his perspective is neither pro- nor anti-pharma, but about recognising pharmaceutical medicine as the socially and morally complex market that it is.
Take a listen for a taste of how every drug contains a multitude of stories, and then check out season 1 of Drug Story if you want a little more.
-
Looking to gene therapy for ocular diseases, with Lance Baldo
8 april 2026 · 13 min
In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Lance Baldo, CEO of Beacon Therapeutics, a clinical-stage biotechnology company harnessing the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases. Lees meer
Baldo discusses the ocular disease landscape, as well as Beacon’s work targeting X-linked retinitis pigmentosa (XLRP) and geographic atrophy (GA), and what the future could look like in terms of innovation in this field.
You can listen to episode 253 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Creating what nature has not from AI and computational molecular biophysics with Kashif Sadiq
31 maart 2026 · 14 min
In a new episode of the pharmaphorum podcast, recorded at BIO-Europe Spring in Lisbon, Portugal, web editor Nicole Raleigh spoke with Kashif Sadiq, founder and CEO of DenovAI Biotech, a company that believes humanity is on the cusp of a protein design revolution that stands to transform both human health and the world around us. Lees meer
Sadiq discusses the company's springboard from AION Labs - with a first-of-its-kind alliance of AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and Amazon Web Services, powered by BioMed X with the support of the Israeli Government.
He also explores harnessing the power of artificial intelligence and computational molecular biophysics, developing foundational technology platforms that can design proteins de novo, and describes the trends and insights from the conference itself this year.
-
On collaboration, computational chemistry, and cutting-edge AI – with Olga Nissan
25 maart 2026 · 11 min
At BIO-Europe Spring 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Dr Olga Nissan, vice president of business development at Evogene, a computational chemistry company, specialising in the generative design of small molecules for the pharmaceutical and agricultural industries. Lees meer
Nissan discusses recent developments at Evogene, including its extended collaboration with Google Cloud to develop and integrate AI agents into Evogene’s ChemPass AI platform, as well as its collaboration with Queensland University of Technology in the non-small cell lung cancer (NSCLC) space. She also speaks to where industry is at in its integration of cutting-edge AI into scientific research.
-
Making AI work where it matters, with Rob DiCicco
17 maart 2026 · 19 min
In a new pharmaphorum podcast, web editor Nicole Raleigh was joined by Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, for a conversation on the barriers and the breakthroughs in making AI work in drug development and clinical trials. Lees meer
DiCicco discusses why AI adoption in clinical trials is so different from preclinical research and development, as well as how synthetic control arms and in silico modelling reshape trial design, and he touches upon the need for making AI solutions meet not just regulatory and scientific standards, but ethical standards, also.
You can listen to episode 250 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Treating genetic disease at scale with tRNA, with Michelle Werner
10 maart 2026 · 25 min
Genetic diseases are notoriously challenging to treat, especially when each condition requires a tailored approach. With over 10,000 known genetic disorders, developing individual therapies for each one has been an immense hurdle, particularly for rare diseases affecting small patient populations. But what if there was a way to address multiple conditions simultaneously, using a single, universal approach? Lees meer
In today’s episode of the pharmaphorum podcast, Michelle Werner, CEO of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine. This approach has the potential to offer hope to millions of patients with rare and ultra-rare diseases, bypassing traditional one-disease-at-a-time models.
Werner discusses how engineered tRNA works, how this technology slots into existing regulatory frameworks, and why this could be a game changer for pharmaceutical development.
You can listen to episode 249 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
AI in clinical development & ‘white space’, with Andrew Mackinnon
3 maart 2026 · 25 min
In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Mackinnon, senior vice president and executive general manager at Medable, about leveraging AI to transform clinical development and accelerate lifesaving therapies to patients. Lees meer
Mackinnon discusses ‘white space’ in R&D, about integrating generative and agentic AI with human-in-the-loop oversight while prioritising patient safety and regulatory, and how all this advances health equity for underserved communities.
You can listen to episode 248 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Collaboration & personalisation in rare disease R&D, with AOP Health’s Melissa Fellner
26 februari 2026 · 12 min
For 30 years, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine, and notably in cardiology and pulmonology, as well as haemato-oncology and advanced therapies. Lees meer
As Rare Disease Day approaches, in a special episode of the pharmaphorum podcast, sponsored by AOP Health, we spoke with Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, at AOP Health, to discuss AOP Health’s work in the rare disease space.
Fellner describes the unique challenges faced in R&D in the rare disease space, as well as how advanced therapies are changing the treatment landscape, and what the future could hold, in terms of technological innovation and personalisation.
What becomes clear is the key role that collaboration plays, from the very early stages of clinical trial design and beyond.
You can listen to episode 246 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
About the interviewee
Melissa Fellner is Vice President of Global Therapeutic Areas at AOP Health. She holds a Master's in Biology, as well as an MBA from The Rady School of Management at University of California, San Diego. Fellner brings more than 25 years of experience across research, clinical development, commercialisation, and global marketing within the pharmaceutical industry. She began her career in 2000 as a research scientist and moved into clinical trial research in the United States and Canada in 2004 with a global contract research organisation.
In 2009, Fellner transitioned into commercialisation consulting, partnering with large pharmaceutical companies on market access and launch strategy. She joined MedImmune, part of AstraZeneca, in 2012 as…
-
Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Alice Valder Curran
24 februari 2026 · 24 min
Slowly but surely – and just in time for the State of the Union – the full picture of the Trump Administration’s Most-Favoured Nations drug pricing policy is coming into focus. At the end of last year, CMS published the draft guidance for its GLOBE and GUARD pricing models, which establish MFN pricing in Medicare Part B and Part D, respectively. And earlier this month TrumpRx – the government’s promised patient-facing discount portal – finally went live. Lees meer
On today’s podcast, Jonah Comstock is joined by Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert, to break down what we know and what we still don’t know about each of these developments.
Among other things, Valder Curran breaks down how the two CMS pilot programmes will work, what statutory authority CMS is leaning on (and whether that authority is likely to be challenged), and how the industry is responding. Comstock and Valder Curran also discuss TrumpRx and how impactful it’s shaping up to be, at least based on what’s been revealed so far. And how do those negotiated MFN deals fit in to all this?
We can’t give you the answers to all your questions about MFN – too much is still up in the air. But this podcast will at least give you an idea of what those open questions are and how they’re likely to play out.
You can listen to episode 246 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
On JPM2026 and healthcare investment today, with Jonah Comstock
17 februari 2026 · 18 min
Following his return from San Francisco and the JP Morgan Healthcare conference last month, editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss what he heard and learned on the ground in California. Lees meer
2026 marked the 44th year of the annual meeting: Comstock shares his top insights, goes into the details from the panel he moderated at the Informa Biotech Showcase, and suggests his key takeaway from this year’s conference.
You can listen to episode 245 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
On addressing drug waste and ensuring access, with Jeff Harper
10 februari 2026 · 12 min
The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs – straining already overburdened health systems. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jeff Harper, head of product at IntelliGuard, about these pressing issues and what hospitals can expect as we progress further into 2026.
The conversation also explores the role digital health technologies like RFID and predictive analytics could play in addressing drug waste and ensuring access, as well as why hospital CFOs and pharmacy leaders are reframing medication management as a strategic priority, not just an operational one
You can listen to episode 244 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
From Buzzword to Strategy: Reverba Global Talks Omnichannel Engagement on the pharmaphorum Podcast
5 februari 2026 · 25 min
The term "omnichannel engagement" has become embedded in today’s healthcare conversations. Yet the biopharmaceutical industry often approaches it superficially – treating it as a trendy buzzword instead of a meaningful strategy for connecting with the sector's two most vital audiences: patients and healthcare providers (HCPs). Lees meer
In this episode of the pharmaphorum podcast, developed in partnership with Reverba Global, editor-in-chief Jonah Comstock sits down with Cheryl Lubbert, co-founder and CEO of Reverba Global, and Carolyn Whiting, SVP of clinical and medical client services, to discuss how a thoughtfully executed omnichannel strategy can empower scientific experts to become effective communicators.
Today's patients actively seek scientifically robust, yet accessible, information about their health conditions, and a well-integrated medical affairs strategy can help deliver that knowledge through the HCPs they trust most.
However, bringing this vision to life requires forward-thinking strategies that build authentic connections, challenge conventional approaches, and dismantle the communication silos that frequently exist in healthcare organisations.
Throughout the episode, Lubbert and Whiting share Reverba Global's methodology for authentic omnichannel engagement with patients and physicians, offering real-world examples and practical perspectives on navigating obstacles and establishing this evolved model.
You can listen to this episode of the pharmaphorum podcast using the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
On quality data for quality learnings, with Lisa Sims
3 februari 2026 · 16 min
Outdated training and behaviours impact patient outcomes and can lead to patient risk. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & operations at Novartis, for a conversation on modern training for pharma and how AI and data – quality data – can help personalise learning at scale.
You can listen to episode 243 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
JPM2026: Broadening AI drug discovery to include the lab, with Yann Gaston-Mathe
27 januari 2026 · 8 min
At the JP Morgan Healthcare conference this year, a lot of the discourse around AI drug discovery focused on making the leap from purely in silico drug discovery operations to real-world operations that are able to incorporate wet lab data in an iterative way. Lees meer
This is easily said, but to do it requires innovating new processes and infrastructures. On the sidelines of the show, pharmaphorum’s Jonah Comstock caught up with Yann Gaston-Mathe, founder and CEO of Iktos, an AI drug discovery company that just signed a billion euro deal with Servier to put this technology into action.
In this quick dispatch from JPM (and we apologise for the shaky audio), Gaston-Mathe describes this shift in AI drug discovery, why it needs to happen, and what it takes, as well as giving some insights on why Servier and Iktos are a good fit as partners.
“You need to think about how effective you are in the transition between the in vitro world and the in silico world,” Gaston-Mathe says. “Building on the data which is available is not enough.”
You can listen to episode 242 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
On AI and equity in the cancer setting, with Mohit Manrao
20 januari 2026 · 22 min
The global impact of digital transformation in the last few decades cannot be understated. And now, of course, artificial intelligence (or AI) is making headlines for its potential to transform lives. Lees meer
In a new pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at AstraZeneca, and president of the AstraZeneca Foundation.
The conversation explores the application of AI in cancer care, some of the most promising potential applications of AI in the life sciences setting generally, as well as AZ’s multi-year partnership with Pangaea Data, focused on advancing precision healthcare with multimodal AI.
Additionally, Manrao discusses how equity gaps in oncology can be minimized, but also the importance of maintaining the human touch when it comes to applying AI in the cancer setting.
You can listen to episode 241 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
JPM2026: AI diagnostics and translational research, with Andrew Beck
15 januari 2026 · 12 min
On-site on the sidelines of JP Morgan Healthcare conference in San Francisco this year, pharmaphorum editor-in-chief Jonah Comstock sat down with Andrew Beck, co-founder and CEO at PathAI. Lees meer
The conversation covers what PathAI has been up to lately in AI within diagnostics in pathology, explores what’s been discussed on the ground at the conference, and also touches upon equality and access to precision diagnostics. Additionally, Beck notes the company’s work in prospective clinical trials in life sciences, as well as co-partnering with pharma.
Having seen an over 10 x growth of adoption of their technology in 2025, Beck also discusses advances in the MASH field.
Listen to this and other conversations from JPM2026 here.
You can listen to episode 240 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Shaping the future of immunodeficiency care, with Dr Jörg Schüttrumpf
6 januari 2026 · 24 min
An increasing prevalence of immunodeficiency and autoimmune disorders has led to increasing demand for plasma-derived immunoglobulin therapies and a need for scalable and sustainable treatment solutions. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Jörg Schüttrumpf, MD, PhD, Chief Scientific Innovation Officer of Grifols and Chief Executive Officer at Biotest, a Grifols company. The conversation explores advancing immunoglobulin (or IG) treatment for immune disorders, looking broadly at the field and current innovation that is working towards redefining how these therapies are delivered, accessed, and optimised for a growing and diverse patient population.
Dr Schüttrumpf also discusses emerging platforms such as recombinant polyclonal therapeutics, as well as the integration of Real World Evidence (RWE) and artificial intelligence (AI) in shaping the future of immunodeficiency care.
You can listen to episode 239 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Aligning with national efforts to modernise cancer diagnostics, with Andrew Newland
30 december 2025 · 15 min
A liquid biopsy is a blood test that detects signs of cancerous tumors, including tumour cells and cancer cell DNA. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Newland, CEO of ANGLE, about why live cell liquid biopsies should become standard in oncology.
Newland explains how current US FDA-approved tests can detect some types of advanced cancers, predict prognosis, and help healthcare providers make treatment decisions. And importantly, Newland describes how live cell liquid biopsies are a UK-developed technology that aligns with national efforts to modernise cancer diagnostics, as well as potentially reduce healthcare costs by minimising ineffective treatments.
You can listen to episode 238 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
Rethinking prescription drug affordability, with Vinay Patel
29 december 2025 · 16 min
It goes without saying that drug pricing and accessibility in the United States are complex indeed. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Vinay Patel, an innovative pharmacist who's set out to transform the healthcare industry, about these intricacies.
Patel discusses some intriguing stories about crafting innovative solutions for employers, revitalising struggling independent pharmacies, and implementing hybrid care models that can make healthcare more attainable for everyone. The conversation touches upon how biosimilars driving pharmaceutical innovation and reducing health costs, the role of telemedicine, also.
You can listen to episode 237 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
-
An AI supercomputer and discovering next-gen brain disorder treatments, with Tarek Samad
23 december 2025 · 17 min
Gefion is Denmark’s first AI supercomputer, named after a goddess in Danish mythology. It is operated by the Danish Centre for AI Innovation (DCAI), a company established with funding from the Novo Nordisk Foundation, the world’s wealthiest charitable foundation, as well as the Export and Investment Fund of Denmark. Lees meer
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tarek Samad, Lundbeck’s senior vice president and head of research, for a conversation on AI – specifically, Lundbeck’s agreement with the DCAI to run and operate Gefion – and accelerating drug discovery and development within the neurological and psychiatric field.
You can listen to episode 236 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.